Anti-CD39 Combination Therapy Promising in Gastric/GEJ Cancer
(MedPage Today) -- NEW ORLEANS -- More than 60% of patients with unresectable gastric/gastroesophageal junction (GEJ) cancer responded to the combination of a CD39 inhibitor and chemoimmunotherapy, a small clinical trial showed.
The data showed...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Gastric (Stomach) Cancer | Gastroenterology | Hematology